MYO · CIK 1369290
What Myomo, Inc. told the SEC could break it.
Myomo's disclosures are those of an unprofitable, single-product company dependent on a thin supply chain and on insurers. All of its revenue comes from one device, the MyoPro myoelectric orthotic, and it relies on a single third-party manufacturer, Cogmedix, to build key subassemblies plus a limited set of component suppliers, mostly without long-term agreements. As a maker reimbursed largely through Medicare and commercial health plans, it is exposed to coverage and reimbursement decisions as well as FDA device regulation, and it imports components subject to tariffs on Canada, Mexico and China. Financially it remains in the red — a $15.6 million net loss in 2025 against a roughly $118 million accumulated deficit — with NYSE American delisting risk given its low, volatile share price.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Regulatory & policy
- tariffs on imports from Canada/Mexico/China affecting componentsmedium
Myomo imports components and faces tariff exposure — a 25% tariff on Canada/Mexico imports (Feb 2025, briefly suspended) and significant China tariffs — which it estimates at <1% gross-margin impact in 2026 but acknowledges could worsen as trade policy evolves.
“For example, on February 1, 2025, the U.S. imposed a 25% tariff on imports from Canada and Mexico, which was subsequently suspended for a period of one month. The U.S. has also imposed significant tariffs on imports from China and other countries, and these tariffs may continue to escalate, depending on the status of trade negotiations.”
SEC filing →As of 2026 - dependence on Medicare/commercial reimbursement and FDA medical-device regulationmedium
MyoPro devices are typically reimbursed by patients' health plans, including Medicare and commercial/managed-care payers, so changes in reimbursement policy or coverage decisions (plus FDA medical-device regulation) directly affect Myomo's revenue.
“MyoPro devices are typically reimbursed by the patient's health insurance plan, which include government health programs in the United States such as Medicare, commercial health insurers and managed care organiza”
Sole-source dependency
- single third-party manufacturer (Cogmedix) for key MyoPro subassemblies; limited component suppliershigh
Myomo depends on a single third-party (Cogmedix) to manufacture key MyoPro subassemblies and on a limited number of suppliers (incl. AB Corp for 3D-printed orthotic components) for other parts, mostly without long-term supply agreements — a sharp single-source manufacturing risk.
“We depend on a single third-party to manufacture key subassemblies for the MyoPro and a limited number of third-party suppliers for certain components of the MyoPro.”
SEC filing →As of 2026
Other disclosures
- unprofitable single-product (MyoPro) business; $118M accumulated deficit; NYSE American delisting riskmedium
Myomo relies on its sole product (MyoPro) for all revenue, incurred a $15.6M net loss in 2025 with a ~$118M accumulated deficit (and 2025 lead-generation/patient-acquisition issues), and risks NYSE American delisting given its low, volatile share price (ranged $0.71–$7.17).
“31, 2025 and 2024 we incurred net losses of $15.6 million and $6.2 million, respectively. At December 31, 2025, we had an accumulated deficit of approximately $118.1 million.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its suppliers
Cogmedix, Inc.
“Some third-party suppliers contract directly with Cogmedix, to supply certain components of the MyoPro products. Cogmedix does not have long-term supply agreements with most of their suppliers and, in many cases, m”
Cited →AB Corp
“We also rely on third-party suppliers, including AB Corp, for 3D printed orthotic components.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch